NCT04574388

Brief Summary

This research aims to understand the impact of conditioned open label placebo (COLP) on opioid consumption and pain after surgery. The hypothesis being tested is that by pairing a non-deceptive placebo pill with regularly prescribed pain killers after surgery, will allow reduction in opioids taken while maintaining the same level of analgesia.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
51

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Nov 2018

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 30, 2018

Completed
6 days until next milestone

First Submitted

Initial submission to the registry

December 6, 2018

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 10, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 10, 2020

Completed
7 months until next milestone

First Posted

Study publicly available on registry

October 5, 2020

Completed
Last Updated

September 13, 2021

Status Verified

September 1, 2021

Enrollment Period

1.3 years

First QC Date

December 6, 2018

Last Update Submit

September 9, 2021

Conditions

Keywords

open label placebo

Outcome Measures

Primary Outcomes (2)

  • self administration of PRN opioids

    daily report of post-discharge opioid use in sub-acute postoperative period, converted into morphine milligram equivalents

    day 3-17

  • acute postoperative pain

    daily brief pain inventory (BPI)

    day 3-17

Study Arms (2)

open label placebo

ACTIVE COMPARATOR

participants will take open label placebo pills TID and in conjunction with other PRN analgesics

Other: open label placebo

treatment as usual

NO INTERVENTION

participants will take PRN analgesics as usual

Interventions

open label placebo pill

Also known as: non-deceptive placebo
open label placebo

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • (1) aged 18-75 years, (2) scheduled for spinal fusion surgery up to, and including 4 levels, (3) able to comprehend and willingness to participate in COLP, (4) willingness to undergo psychophysical and psychosocial testing (5) willingness to participate in long-term follow-up.

You may not qualify if:

  • (1) delirium, psychosis, or other cognitive impairment limiting completion of study procedures (2) non-English

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States

Location

Related Publications (1)

  • Flowers KM, Patton ME, Hruschak VJ, Fields KG, Schwartz E, Zeballos J, Kang JD, Edwards RR, Kaptchuk TJ, Schreiber KL. Conditioned open-label placebo for opioid reduction after spine surgery: a randomized controlled trial. Pain. 2021 Jun 1;162(6):1828-1839. doi: 10.1097/j.pain.0000000000002185.

Study Officials

  • Kristin Schreiber, M.D., Ph.D.

    Brigham and Women's Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor, Principle Investigator

Study Record Dates

First Submitted

December 6, 2018

First Posted

October 5, 2020

Study Start

November 30, 2018

Primary Completion

March 10, 2020

Study Completion

March 10, 2020

Last Updated

September 13, 2021

Record last verified: 2021-09

Locations